⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

September 22, 2025Open Access

Table S4 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors

John D. Powderly Martina Imbimbo Antoîne Italiano Patricia Martín-Romano Meredith McKean Teresa Macarulla Eduardo Castañón Álvarez Benedito A. Carneiro Raymond Mager Vicky Barnhart Steven Eck Elina Murtomaki Arsène‐Bienvenu Loembé Yun He Zachary A. Cooper Eric Tu Chunling Fan Agnes Boyer Chamard Carine Paturel Paula G. Fraenkel Antoine Hollebecque

View Full Paper

Ask AI

Bookmark

Share

Key Points

IPH5201 shows promising pharmacokinetic parameters following administration, indicating potential effectiveness.
A single intravenous dose of IPH5201 was administered, providing key data for advanced solid tumor therapy.
The combination of IPH5201 and durvalumab highlights a novel approach for treating these tumors.
Pharmacokinetic analysis offers insights into the drug's distribution and clearance in patients.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Data reveals PK parameters of IV IPH5201 in advanced solid tumors, suggesting its role with durvalumab.

Abstract

IPH5201 PK Parameters following a single dose of intravenous IPH5201.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Powderly et al. (2025) studied this question.

synapsesocial.com/papers/68d4725631b076d99fa6b15d https://doi.org/10.1158/2767-9764.30177694

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table S5 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors2025
2Table S3 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors2025
3Table S1 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors2025
4Table 1 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors2025
5Table S2 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors2025